Here are three things to know.
- The Auvi-Q 0.1 milligram auto-injector is intended to treat infants and young children who weigh 16.5 to 33 pounds and are at risk for serious allergic reactions.
- The device contains a shorter needle and lower epinephrine dose than other Auvi-Q auto-injectors already on the market.
- Kaléo expects Auvi-Q 0.1 milligram to be available for patients by mid-2018.
More articles on supply chain:
4 ways the FDA is addressing the saline bag shortage
FDA approves first pill with digital ingestion tracking system
Mylan lays off up to 300 employees
